SCHEMBL4337068

SCHEMBL4337068

CC(C)C(=O)Nc1nc2c(c(=O)[nH]1)N=C[N]2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PAX3 P23760 1/20 0.39
FOXO1 Q12778 1/20 0.39
KDM4E B2RXH2 3/20 0.39
NOS1 P29475 1/20 0.38
TSHR P16473 1/20 0.36
ADORA1 P30542 1/20 0.34
TP53 P04637 2/20 0.34
ALDH1A1 P00352 3/20 0.33
GAA P10253 2/20 0.33
GDA Q9Y2T3 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MDM4 O15151 1/20 0.33
FFAR2 O15552 1/20 0.32
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
GLA P06280 1/20 0.32
HPGD P15428 1/20 0.32
KMT2A Q03164 1/20 0.32
HSD17B10 Q99714 1/20 0.32
RCE1 Q9Y256 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17260466 0.84 GDA (0.47) KDM4ETSHRALDH1A1GAAGDA
SCHEMBL10590403 0.77 NLRP3 (0.40) KDM4ETSHRALDH1A1NPSR1ALOX15
SCHEMBL25324519 0.77 RAB9A (0.51) PAX3FOXO1KDM4ETSHRADORA1
SCHEMBL17260490 0.74 POLB (0.35) KDM4ETSHRALDH1A1MEN1LMNA
SCHEMBL537506 0.71 ADORA1 (0.41) KDM4ENOS1TSHRADORA1ALDH1A1
SCHEMBL22036469 0.70 ALDH1A1 (0.43) PAX3FOXO1KDM4ENOS1TSHR
SCHEMBL25322413 0.70 GSK3B (0.37) KDM4ENOS1TSHRTP53ALDH1A1
SCHEMBL442818 0.68 NOS1 (0.45) PAX3FOXO1KDM4ENOS1TSHR
SCHEMBL735411 0.67 GDA (0.72) GDA
SCHEMBL8886595 0.67 NOS1 (0.38) PAX3FOXO1KDM4ENOS1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-59125895-A None JP disclosed
JP-59106297-A None JP disclosed
US-20230257413-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF RIKEN GENESIS CO., LTD. (JP) 2023-08-17 US disclosed
EP-4219517-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF Riken Genesis Co., Ltd. (JP) 2023-08-02 EP disclosed
WO-2023127857-A1 NOVEL ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE OF SAME 株式会社理研ジェネシス 2023-07-06 WO disclosed
CN-116322706-A Novel artificial nucleic acid, method for producing same, and use thereof 株式会社理真思 2023-06-23 CN disclosed
CN-113646007-A Novel artificial nucleic acid, method for producing same, and use thereof 希森美康株式会社 2021-11-12 CN disclosed
WO-2020203896-A1 NEW ARTIFICIAL NUCLEIC ACID, PRODUCTION METHOD THEREFOR, AND USE THEREOF シスメックス株式会社 2020-10-08 WO disclosed
US-7612197-B2 Reacting a nucleophil with OH group with an electrophil to form an adduct, reacting adduct with a reagent selected from oxidizing, sulfurizing or selenizing agents to produce hydroxy protected oligonucleotide, heating to deprotect hydroxy protecting group such as 2-(2-pyridyl)aminoethoxycarbonyl The United States of America as repesented by the Secretary of the Department of Health and Human Services (US) 2009-11-03 US disclosed
US-20060281911-A1 Thermolabile hydroxyl protecting groups and methods of use GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) 2006-12-14 US disclosed
EP-0463712-A2 Polynucleotide phosphorodithioates as therapeutic agents for retroviral infections UNIVERSITY PATENTS, INC. (US) 1992-01-02 EP disclosed
WO-1990012022-A1 POLYNUCLEOTIDE PHOSPHORODITHIOATES AS THERAPEUTIC AGENTS FOR RETROVIRAL INFECTIONS UNIVERSITY PATENTS, INC. (US) 1990-10-18 WO disclosed
EP-0378615-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES COMPETITIVE TECHNOLOGIES INC. (US) 1990-07-25 EP disclosed
WO-1989011486-A1 NUCLEOSIDE AND POLYNUCLEOTIDE THIOPHOSPHORAMIDITE AND PHOSPHORODITHIOATE COMPOUNDS AND PROCESSES UNIVERSITY PATENTS, INC. (US) 1989-11-30 WO disclosed
EP-0107278-B1 MOLECULAR CLONING OF THE GENE FOR HUMAN ANTI-HAEMOPHILIC FACTOR IX NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1989-11-15 EP disclosed
EP-0316558-A1 Factor IX DNA BTG INTERNATIONAL LIMITED (GB) 1989-05-24 EP disclosed
JP-S59125895-A SYNTHESIS OF HUMAN GROWTH HORMONE GENE RIKAGAKU KENKYUSHO 1984-07-20 JP disclosed
JP-S59106297-A SYNTHESIS OF CARBOXY-TERMINATED GENE OF HUMAN GROWTH HORMONE RIKAGAKU KENKYUSHO 1984-06-19 JP disclosed
EP-0107278-A1 Molecular cloning of the gene for human anti-haemophilic factor IX NATIONAL RESEARCH DEVELOPMENT CORPORATION (GB) 1984-05-02 EP disclosed
WO-1984000560-A1 MOLECULAR CLONING OF THE GENE FOR HUMAN ANTI-HAEMOPHILIC FACTOR IX NAT RES DEV (GB) 1984-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257413-A1 ARTIFICIAL NUCLEIC ACID, METHOD FOR PRODUCING SAME, AND USE THEREOF NSUN2, NSUN3, POLRMT PAX3 1025/4885FOXO1 3288/4885KDM4E 2076/4885
US-20060281911-A1 Thermolabile hydroxyl protecting groups and methods of use ADH1A, CYP2E1, ADH1C PAX3 4347/4885FOXO1 350/4885KDM4E 2815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.